

52 / 129

Fig. 52

DR	Diversity	Prognosis		Prognosis		Prognosis		Prognosis		Prognosis	
		Equivalence	Total (+)	Total (homo)	Total	Total (+) vs (-)	Total (homo)	Stomach	Stomach	Total (+) vs (-)	Total (homo)
5	arp_25	KR	K=R	K(+)hetero Rhombohetero	RR78.8	F(+)>(+)	F(+)>(+)	Stomach	Stomach	RR71.4	RR71.4
6	arp_24	FL	F=L	Abnormal hetero	AA76.8	AA76.8	AA76.8			UL60.9	UL60.9
13	arp_17	AT	A=T	Abnormal hetero	W77.8	W77.8	W77.8			AA67.8	AA67.8
14	arp_16	AV	A=V	Abnormal hetero	SS83.36	SS83.36	SS83.36			WT71.4	WT71.4
29	arp_1	AS	A=S							SS100	SS100
33	arp4	QR	Q=R		QR68.3					AA76.8	AA76.8
38	arp9	EKW	9K=11D=26Y=28H=30G		KW74.2					KW75.8	KW75.8
39	arp10	EQY	10E=31V=38A=40Y=		EY83.3					EY75	EY75
40	arp11	DGLPSV	(169Q=(166R)								
41	arp12	KT	11G=13Y=14E=14=K25								
42	arp13	FGHRSY	Q=25R=30L, 11S=12K=12T, 11P=13R								
43	arp14	EK	13F=31F=31								
45	arp16	HOY	E=K		EE66.2						
55	arp25	OR	Q=R		HQ71.50						
57	arp28	DEH	28H=30G		LY70.2						
59	arp30	CDHRY	30H=37L=38L=85A=85V								
60	arp31	FIV	31V=38A=40F=40Y, 31	(F=1)							

53 / 129

Fig. 53

DR	Diversity		Prognosis		Prognosis		Prognosis		Prognosis		Prognosis	
	Equivalence	Total (+)	Total (homo)	Total	Total (+) vs (-)	Total (homo)	Stomach	Total (+) vs (-)	Total (homo)	Stomach	Total (+) vs (-)	Total (homo)
6.1	arp32	HY	H=Y				HY66.9			YY68		
6.2	arp33	HN	H=N				NN66.7			HH71.4		
6.6	arp37	FLNS	Y=S				LL800			FS73.4		
6.7	arp38	ALV					LL800			AV73.8		
6.9	arp40	FY	F=Y				FY73.1			FY71.5		
7.6	arp47	FY	F=Y				FY67.4			YY68.9		
8.6	arp57	ADSV					AV73.7C			AD72.5,		
8.7	arp58	AE	A=E				AE67			SV72.5		
8.9	arp60	HY	H=Y				HS73.7			AE71.1		
9.6	arp67	FL					FI68.5			HY68.4		
9.9	arp70	DOR					DD69.4			FI72.2		
10.0	arp71	AERK					AR63.5,			DD72.7		
							ER67.2,					
							AET2.6					
							AA66.3					
										AA68.1		
103	arp74	AELQR	R=N				LR80			AA100.0		
106	arp77	NT	N=T				TT66.4			TT68.2		
107	arp78	VY	V=Y				YY67.1			YY68.6		

54 / 129

Fig. 54

DR	Diversity	Prognosis		Prognosis		Prognosis		Prognosis		Prognosis	
		Diversity	Equivalence	Total (+)	Total (homo)	Total	Total	Total (homo)	Stomach	Stomach	Total (+) vs (-)
		Total	Total	Stomach	Stomach	(-)	Other cancers	Other cancers	Total	Total	Total (+) vs (-)
114	ap85	AV	A=V			AAB0			W68.1		
115	ap86	GV	G=V			GG68.5			W69.4		
125	ap96	EHQY				EE100			EE100		Q <sup>+</sup>
127	ap98	EK	98E=98K=104A=142V			EK68.5			EK72.1		ReP029909
133	ap104	AS	A=S			AST0.5			AS72.1		
149	ap120	NS	S=N			NN77.9			NN72.9		
162	ap133	LR	133L=133R=142M=142V			RR67.5			LL69.7		ReP029909
169	ap140	AT				TT71.5			TT74.1		
171	ap142	MV	M=V			W67.5			MM69.7		W672X
178	ap149	HOY	H=Q			HH68.1			HH70.8		
195	ap166	OR	Q=R			RR67			QR68.6		
209	ap180	LV	L=V			LL75.1			LL70.1		
210	ap181	MT				TT67.3			TT69		
218	ap189	RS	R=S			SS100			SS100		
260	ap231	PQ	P=Q			QQ66.7			QQ67.9		
262	ap233	RT	R=T			TT67.4			RR78.2		R_Theore(1)
		All	survived			DR11GLGV			DR30CLC		Shome
						LL(5)			C4)		

୩୩

၁၃၁

58 / 129

58

	Treatment Effect	Treatment Effect	Treatment Effect		DR	DR	DR
			Total (+) vs (-)	Total (homo)			
DR	Diversity	Equivalence	Other cancers	Other cancers			
arp_25	KR	K=R					
arp_24	FL	F-L					
arp_17	AT	A=T					
arp_16	AV	A=V					
arp_1	AS	A=S					
arp_4	QR	Q=R					
arp9	EKW	9K=11D=26Y ≈28H≈30G					
arp10	EQY	10E=31V=36A ≈40Y≈166Q ≈168R					
arp11	D3LPSV	11G=13Y=14 E=14≈K25Q≈ 25R≈30L 11S≈12K≈12T 11P≈13R					
arp12	KT	13F=31V=31H					
arp13	FG4RSY						
arp14	EK	E=K			#		
arp16	HQY				QQ100	YY6	30
arp25	QR	Q=R					
arp26	FLY				#		
arp28	DEH	28H=30G			#		
arp30	CDHRY	30H=37V=38L ≈85A≈65Y					
arp31	FIN	31V≈38A≈40F ≈40Y 31V(F≈1)					

五  
59

59 / 129

Diversity	Treatment Effect		Treatment Effect	Treatment Effect		DR	DR	DR
	Equivalence	Total (+) vs (-)		Total (none)	Cancer in Family			
DR	Diversity	HY	Other cancers	Other cancers	Other cancers			
arp32			Chemotherapy Y(+/-)	Chemotherapy HY				
			Immunotherapy Y(+/-)	Heterozygote				
			Chemotherapy H(+/-)	immunotherapy heterozygote				
				chemo. Chemotherapy				
				Y heterozygote				
				immunotherapy				
				Y heterozygote				
arp33	HN	H=N						
arp37	FLNSY	F=S						
			Chemotherapy H(+/-)	no adjuvant therapy				
			Heterozygote	YY(111) Chemotherapy				
				FS(101) immunotherapy				
				NS(001)				
				#				
arp38	ALV							
arp40	FY	F=Y						
arp47	FY	F=Y						
arp57	ADSV		Chemotherapy A(+/-)	no adjuvant therapy				
			Chemotherapy A(+/-)	SW1818 Chemotherapy				
			chemo. none	W1857 immunotherapy				
			immunotherapy Sheeroid	DS1083				
			chemo					
arp58	AE	A=E						
arp60	HY		Chemotherapy H(+/-)	Chemotherapy SS(5573)				
			Heterozygote	immunotherapy HY(753)				
				no adjuvant therapy F(857)				
				W782				
arp67	FIL							
arp70	DQR							
arp71	AERK							
arp73	AG	R=73G=74	no adjuvant therapy	no adjuvant therapy AR(43)				
		R=74N=77N=771						
arp74	AELQR	R=N	no adjuvant therapy L	no adjuvant therapy AELQR				
		771						
arp77	NT	N=T						
arp78	VY	V=Y						

60

60 / 129

Treatment Effect	Treatment Effect	DR		DR		DR	
		Total (+) vs (-)	Total (homo)	Cancer in Family	Metastases	Total (ratio of cancer)	Smoking
Diversity	Equivalence	Other cancers	Other cancers	Other cancers	Other cancers	Other cancers	Other cancers
DR	Diversity	A=V					
arp85	AV						
arp85	GV	G=V					
arp93	EHQY						
arp98	EK	98E-98K=104	Immunotherapy K(+)(-)	Chemotherapy	Chemotherapy	Chemotherapy	Chemotherapy
arp104	AS	A=104S		Chemotherapy	Chemotherapy	Chemotherapy	Chemotherapy
arp120	NS	S=N		Immunotherapy S(+)(-)	Immunotherapy	Immunotherapy	Immunotherapy
arp133	LR	133L=133R=1	no adjuvant therapy	no adjuvant therapy	no adjuvant therapy	no adjuvant therapy	no adjuvant therapy
		42M=142V	R(+)(-)	R(+)(-)	R(+)(-)	R(+)(-)	R(+)(-)
arp140	AT	M=V					
arp142	MV		no adjuvant therapy	no adjuvant therapy	no adjuvant therapy	no adjuvant therapy	no adjuvant therapy
arp149	HOY	H=Q					
arp164	FY						
arp186	OR	O=R					
arp180	LV	L=V					
arp181	MT						
arp189	RS	R=S					
arp231	PQ	P=Q					
arp333	RT	R=T	Immunotherapy (T+)(-)	Immunotherapy R(+)(-)	Immunotherapy R(+)(-)	Immunotherapy R(+)(-)	Immunotherapy R(+)(-)
All	survived						

३८

67  
—  
26

Fig. 62

62 / 129

